1. Rouzer CA, Marnett LJ. J Lipid Res. 2009;50(Suppl):S29. [PubMed] 2. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Int J Biochem Cell Biol. 1999;31:551. [PubMed] 3. Cohn SMZ, Schloemann S, Tessner T, Seibert K, Stenson WF. J Clin Invest. 1997;99:1367. [PMC free article] [PubMed] 4. Hla T, Neilson K. Proc Natl Acad Sci USA. 1992;89:7384. [PubMed] 5. Wang D, Dubois RN. Semin Oncol. 2004;31(1 Suppl 3):64. [PubMed] 6. Menter DG, Schilsky RL, DuBois RN. Clin Cancer Res. 2010;16:1384. [PubMed] 7. Parrett M, Harris R, Joarder F, Ross M, Clausen K, Robertson F. Int J Oncol. 1997;10:503. [PubMed] 8. Hwang D, Scollard D, Byrne J, Levine E. J Natl Cancer Inst. 1998;90:455. [PubMed] 9. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. Cancer. 2000;89:2637. [PubMed] 10. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Cancer Res. 2000;60:1306. [PubMed] 11. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE. Anticancer Res. 2001;21:3425. [PubMed] 12. Psaty BM, Furberg CD. N Engl J Med. 2005;352:1133. [PubMed] 13. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Lancet. 2005;365:475. [PubMed]
14. Kimura T, Noguchi Y, Nakao A, Suzuki K, Ushiyama S, Kawara A, Miyamoto M. 799823. EP. 1997:A1.
15. Rao PP, Grover RK. IDrugs. 2009;12:711. [PubMed] 16. Moberly JB, Xu J, Desjardins PJ, Daniels SE, Bandy DP, Lawson JE, Link AJ, Truitt KE. Clin Ther. 2007;29:399–412. [PubMed] 17. Rohatagi S, Kastrissios H, Sasahara K, Truitt K, Moberly JB, Wada R, Salazar DE. Br J Clin Pharmacol. 2008;66:60. [PubMed] 18. Ushiyama S, Yamada T, Murakami Y, Kumakura S, Inoue S, Suzuki K, Nakao A, Kawara A, Kimura T. Eur J Pharmacol. 2008;578:76. [PubMed] 19. Kiguchi K, Ruffino L, Kawamoto T, Franco E, Kurakata S, Fujiwara K, Hanai M, Rumi M, DiGiovanni J. Mol Cancer Ther. 2007;6:1709. [PubMed] 20. Senzaki M, Ishida S, Yada A, Hanai M, Fujiwara K, Inoue S, Kimura T, Kurakata S. Int J Cancer. 2008;122:1384. [PubMed] 21. Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S. Cancer. 2011;117:809. [PubMed]
22. Kojima S, Ooyama J. 2008020617A. WO. 2008
23. Okazaki R, Kojima S. 20050148780. US. 2005
24. Dorr AA, Lubell WD. Can J Chem. 2007;85:1006.
25. Synthesis of 1-(4-ethoxy-phenyl)-3-methyl-hex-4-en-1-one (8): To a stirred suspension of CuCN (1.8 g, 20.0 mmol) in 50 mL of dry THF at −78°C under argon, a solution of 1-propenylmagnesium bromide (133.2 mmol, 265 mL of 0.5 M solution in THF) was added dropwise. The slurry was stirred for an additional 30 min and then a solution of methyl 4-ethoxybenzoate (6.0 g, 33.3 mmol) in 60 mL of dry THF was added slowly. The stirred reaction mixture was allowed to warm to room temperature overnight. The reaction was quenched with ice cold saturated aqueous NaH2PO4 (100mL) and the mixture was extracted with ether (4 × 100 mL). The combined ether extracts were washed with brine (2 × 100mL), dried (MgSO4), filtered, and evaporated to dryness. The crude homoallylic ketone was purified by silica gel flash chromatography using a gradient of ethyl acetate in hexane as the eluent to give 8 (7.4 g, 95%) as a colorless oil. 1H NMR (CDCl3, 300.0 MHz) δ 1.04–1.07 (m, 3H), 1.44 (t, J = 6.9 Hz, 3H), 1.6–1.64 (m, 3H), 2.8–2.96 (m, 2.5H), 3.2 (m, 0.5H), 4.1 (q, J = 6.9 Hz, 2H), 5.25 (m, 0.5 H), 5.34–5.46 (m, 1.5H), 6.92 (d, J = 9.0 Hz, 2H), 7.92 (d, J = 9.0 Hz, 2H). 13C NMR (CDCl3, 75.0 MHz) δ 12.9, 14.6, 17.9, 20.4, 21.0, 28.4, 33.0, 45.4, 45.5, 63.7, 114.1, 123.1, 123.4, 130.2, 130.3, 135.5, 136.0, 141.9, 162.7, 198.1. M+H Calcd: 233.1542; Found, 233.2482.
26. Synthesis of Apricoxib (1): Homoallylic ketone (8) (5.0 g, 21.53 mmol) in 180 mL of CH2Cl2/MeOH (1:5) was treated with ozone bubbles at −78°C until a blue coloration persisted. The solution was purged with argon, 8.0 mL of dimethylsulphide (21.5 mmol) was added, and the reaction mixture then warmed slowly to rt overnight. The solvent was evaporated under vacuum to give 7 which was then diluted with 100 mL of 40 % acetic acid in acetonitrile, (v/v) and sulphanilamide (4.0 g, 23.2 mmol) was added. The mixture was refluxed until complete consumption of 1,4-dicarbonyl compound was detected by TLC (ca 3 h). After cooling to room temperature, the product was concentrated under vacuum and diluted with 250 mL of ethyl acetate. The organic layer then washed with saturated Na2CO3 solution (3 × 50 mL) followed by brine (1 × 50 mL), dried (MgSO4), and evaporated to dryness. The crude brown material was purified by silica gel flash chromatography using a gradient of EtOAc in hexane to give apricoxib as white solid (5.5 g, 15.43 mmol, 71%). m.p. 161–163°C (lit. 135–139°C14). 1H NMR (CDCl3, 300.0 MHz) δ 1.32 (t, J = 6.9 Hz, 3H), 2.1 (s, 3H), 3.92 (q, J = 6.9 Hz, 2H), 4.95 (s, 2H), 6.14 (m, 1H), 6.63 (m, 1H), 6.69 (d, J = 6.6 Hz, 2H), 6.94 (d, J = 6.6 Hz, 2H), 7.13 (d, J = 6.6 Hz, 2H), 7.74 (d, J = 6.6 Hz, 2H). 13C NMR (CDCl3, 75.0 MHz) δ 11.7, 14.8, 63.4, 82.4, 113.2, 114.4, 121.0, 121.1, 124.9, 125.2, 127.4, 129.7, 133.6, 138.7, 144.2, 158.0 M+H Calcd: 357.1273; Found, 357.1252.
27. PGE2 production in inflammatory breast cancer cells. SUM149 or SUM190 cells were cultured in F12 media (Invitrogen) supplemented with 10% fetal bovine serum, 5 μg/mL insulin (Sigma-Aldrich, St Louis, MO), 1 μg/mL hydrocortisone (Sigma-Aldrich), and antibiotic/antimycotic (Invitrogen/Life Technologies, Carlsbad, CA). Cells were seeded in triplicate in six-well tissue culture plates in a humidified cell culture incubator at 37°C with 5% CO2. When cells reached 80% confluence, culture media was removed by aspiration, cells were washed once with sterile PBS and fresh medium containing the indicated COX-2 inhibitor, either Apricoxib, or Celecoxib at concentrations of 0.1, 1, and 10 μM, or an equivalent amount of DMSO used as the vehicle control was added. Cells were pre-incubated for 2 hours in the presence of either the COX-2 inhibitor or DMSO at 37°C. Following the 2 hour pre-incubation time period, PGE2 production was stimulated by the addition of sodium arachidonate (Cayman Chemical, Ann Arbor, MI), added directly to growth medium, with gentle agitation, to a final concentration of 10 μM, and incubated for an additional 2 hours. Conditioned supernatant was then isolated from cells and stored at −80°C until further analysis. Following removal of supernatants, cells were immediately trypsinized and cell number was assessed. PGE2 was assayed from conditioned supernatant using a competitive enzyme immunoassay specific to PGE2 (Cayman Chemical), as recommended by the manufacturer. The concentration of PGE2 was normalized to total cell number per well, expressed as pg PGE2/mL conditioned supernatant/1000 cells. Assays were run three times and are expressed and mean ± standard deviation.